An update on the role of intestinal cytochrome P450 enzymes in drug disposition

Kaminsky, 2003, The small intestine as a xenobiotic-metabolizing organ, Drug Metab Dispos, 31, 1520, 10.1124/dmd.31.12.1520 Ding, 2003, Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts, Annu Rev Pharmacol Toxicol, 43, 149, 10.1146/annurev.pharmtox.43.100901.140251 van Herwaarden, 2009, How important is intestinal cytochrome P450 3A metabolism?, Trends Pharmacol Sci, 30, 223, 10.1016/j.tips.2009.02.003 Thelen, 2009, Cytochrome P450-mediated metabolism in the human gut wall, J Pharm Pharmacol, 61, 541, 10.1211/jpp.61.05.0002 Zhang, 1999, Characterization of human small intestinal cytochromes P-450, Drug Metab Dispos, 27, 804 Paine, 2006, The human intestinal cytochrome P450 "pie", Drug Metab Dispos, 34, 880, 10.1124/dmd.105.008672 Obach, 2001, Metabolic characterization of the major human small intestinal cytochrome p450s, Drug Metab Dispos, 29, 347 Zeldin, 1997, CYP2J subfamily cytochrome P450s in the gastrointestinal tract: expression, localization, and potential functional significance, Mol Pharmacol, 51, 931, 10.1124/mol.51.6.931 Xu, 2013, Cytochrome P450 2J2: distribution, function, regulation, genetic polymorphisms and clinical significance, Drug Metab Rev, 45, 311, 10.3109/03602532.2013.806537 Lee, 2010, Identification of novel substrates for human cytochrome P450 2J2, Drug Metab Dispos, 38, 347, 10.1124/dmd.109.030270 Rylander, 2001, Identification and tissue distribution of the novel human cytochrome P450 2S1 (CYP2S1), Biochem Biophys Res Commun, 281, 529, 10.1006/bbrc.2001.4390 Nishida, 2010, Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1, Mol Pharmacol, 78, 497, 10.1124/mol.110.065045 Xiao, 2011, Cytochrome P450 2S1 is reduced by NADPH-cytochrome P450 reductase, Drug Metab Dispos, 39, 944, 10.1124/dmd.111.039321 Wang, 2012, Bioactivation of fluorinated 2-aryl-benzothiazole antitumor molecules by human cytochrome P450s 1A1 and 2W1 and deactivation by cytochrome P450 2S1, Chem Res Toxicol, 25, 1740, 10.1021/tx3001994 Choong, 2015, Developmental regulation and induction of cytochrome P450 2W1, an enzyme expressed in colon tumors, PLoS One, 10, e0122820, 10.1371/journal.pone.0122820 Chen, 2015, Ontogenic expression of human carboxylesterase-2 and cytochrome P450 3A4 in liver and duodenum:postnatal surge and organ-dependent regulation, Toxicology, 330, 55, 10.1016/j.tox.2015.02.007 Betts, 2015, Expression of CYP3A4 and CYP3A7 in human foetal tissues and its correlation with nuclear receptors, Basic Clin Pharmacol Toxicol, 117, 261 Cizkova, 2014, Time-dependent expression of cytochrome p450 epoxygenases during human prenatal development, Organogenesis, 10, 53, 10.4161/org.27911 Törrönen, 1994, Hepa-1 enzyme induction assay as an in vitro indicator of the CYP1A1-inducing potencies of laboratory rodent diets in vivo, Life Sci, 55, 1945, 10.1016/0024-3205(94)00527-3 Cummings, 1995, Inhibitory effect of dietary 4-ipomeanol on DNA adduct formation by the food mutagen 2-amino-3-methylimidazo[4,5-f]quinoline (IQ) in male CDF1 mice, Carcinogenesis, 16, 2523, 10.1093/carcin/16.10.2523 Muto, 1997, Induction and inhibition of cytochrome P450 isoforms by imazalil, a food contaminant, in mouse small intestine and liver, Xenobiotica, 27, 1215, 10.1080/004982597239804 Emoto, 2000, Characterization of cytochrome P450 enzymes involved in drug oxidations in mouse intestinal microsomes, Xenobiotica, 30, 943, 10.1080/00498250050200104 Xie, 2000, Induction of mouse CYP2J by pyrazole in the eye, kidney, liver, lung, olfactory mucosa, and small intestine, but not in the heart, Drug Metab Dispos, 28, 1311 Zhang, 2003, Characterization of mouse small intestinal cytochrome P450 expression, Drug Metab Dispos, 31, 1346, 10.1124/dmd.31.11.1346 Uno, 2008, Basal and inducible CYP1 mRNA quantitation and protein localization throughout the mouse gastrointestinal tract, Free Radic Biol Med, 44, 570, 10.1016/j.freeradbiomed.2007.10.044 Renaud, 2011, Tissue distribution and gender-divergent expression of 78 cytochrome P450 mRNAs in mice, Toxicol Sci, 124, 261, 10.1093/toxsci/kfr240 Hersman, 2014, A targeted proteomics approach for profiling murine cytochrome P450 expression, J Pharmacol Exp Ther, 349, 221, 10.1124/jpet.113.212456 Nakanishi, 2010, Regional distribution of cytochrome p450 mRNA expression in the liver and small intestine of cynomolgus monkeys, Drug Metab Pharmacokinet, 25, 290, 10.2133/dmpk.25.290 Nakanishi, 2011, Regional distribution of drug-metabolizing enzyme activities in the liver and small intestine of cynomolgus monkeys, Drug Metab Pharmacokinet, 26, 288, 10.2133/dmpk.DMPK-10-NT-101 Nishimuta, 2011, Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans, Drug Metab Pharmacokinet, 26, 300, 10.2133/dmpk.DMPK-10-SH-119 Komura, 2011, In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences, Drug Metab Rev, 43, 476, 10.3109/03602532.2011.597401 Yoda, 2012, Characterization of intestinal and hepatic P450 enzymes in cynomolgus monkeys with typical substrates and inhibitors for human P450 enzymes, Xenobiotica, 42, 719, 10.3109/00498254.2012.656732 Uehara, 2014, Immunochemical detection of cytochrome P450 enzymes in small intestine microsomes of male and female untreated juvenile cynomolgus monkeys, Xenobiotica, 44, 769, 10.3109/00498254.2014.895882 Uehara, 2015, Immunochemical quantification of cynomolgus CYP2J2, CYP4A and CYP4F enzymes in liver and small intestine, Xenobiotica, 45, 124, 10.3109/00498254.2014.952800 Uehara, 2016, Molecular cloning, tissue distribution, and functional characterization of marmoset cytochrome P450 1A1, 1A2, and 1B1, Drug Metab Dispos, 44, 8, 10.1124/dmd.115.067561 Uehara, 2015, Marmoset cytochrome P450 2D8 in livers and small intestines metabolizes typical human P450 2D6 substrates, metoprolol, bufuralol and dextromethorphan, Xenobiotica, 45, 766, 10.3109/00498254.2015.1019595 Shimizu, 2014, Qualitative de novo analysis of full length cDNA and quantitative analysis of gene expression for common marmoset (Callithrix jacchus) transcriptomes using parallel long-read technology and short-read sequencing, PLoS One, 9, e100936, 10.1371/journal.pone.0100936 Nishimuta, 2013, Species differences in hepatic and intestinal metabolic activities for 43 human cytochrome P450 substrates between humans and rats or dogs, Xenobiotica, 43, 948, 10.3109/00498254.2013.787155 Palasz, 2012, Age-related changes in the mRNA levels of CYP1A1, CYP2B1/2 and CYP3A1 isoforms in rat small intestine, Genes Nutr, 7, 197, 10.1007/s12263-011-0240-z Bueters, 2013, Rat poorly predicts the combined non-absorbed and presystemically metabolized fractions in the human, Xenobiotica, 43, 607, 10.3109/00498254.2012.752117 Heikkinen, 2015, Quantitative ADME proteomics—CYP and UGT enzymes in the Beagle dog liver and intestine, Pharm Res, 32, 74, 10.1007/s11095-014-1446-8 Heikkinen, 2013, In vitro to in vivo extrapolation and physiologically based modeling of cytochrome P450 mediated metabolism in beagle dog gut wall and liver, Mol Pharm, 10, 1388, 10.1021/mp300692k Matsubara, 2004, Isolation and characterization of a new major intestinal CYP3A form, CYP3A62, in the rat, J Pharmacol Exp Ther, 309, 1282, 10.1124/jpet.103.061671 Do, 2012, TLR2 controls intestinal carcinogen detoxification by CYP1A1, PLoS One, 7, e32309, 10.1371/journal.pone.0032309 Albérich, 2014, Ivermectin exposure leads to up-regulation of detoxification genes in vitro and in vivo in mice, Eur J Pharmacol, 740, 428, 10.1016/j.ejphar.2014.06.052 Kudo, 2010, Differences in the pharmacokinetics of CYP3A substrates in TSOD and streptozotocin-induced diabetic mice, Xenobiotica, 40, 282, 10.3109/00498251003596809 Patoine, 2014, Modulation of CYP3A expression and activity in mice models of type 1 and type 2 diabetes, Pharmacol Res Perspect, 2, e00082, 10.1002/prp2.82 Boušová, 2016, Influence of diet supplementation with green tea extract on drug-metabolizing enzymes in a mouse model of monosodium glutamate-induced obesity, Eur J Nutr, 55, 361, 10.1007/s00394-015-0856-7 Pondugula, 2015, Diindolylmethane, a naturally occurring compound, induces CYP3A4 and MDR1 gene expression by activating human PXR, Toxicol Lett, 232, 580, 10.1016/j.toxlet.2014.12.015 Wang, 2013, Piperine activates human pregnane X receptor to induce the expression of cytochrome P450 3A4 and multidrug resistance protein 1, Toxicol Appl Pharmacol, 272, 96, 10.1016/j.taap.2013.05.014 Qiu, 2012, Andrographolide inhibits the expression and metabolic activity of cytochrome P450 3A4 in the modified Caco-2 cells, J Ethnopharmacol, 141, 709, 10.1016/j.jep.2011.09.002 Takeshita, 2011, Acetyl tributyl citrate, the most widely used phthalate substitute plasticizer, induces cytochrome P450 3A through steroid and xenobiotic receptor, Toxicol Sci, 123, 460, 10.1093/toxsci/kfr178 Matuskova, 2011, Effects of Lactobacillus casei on the expression and the activity of cytochromes P450 and on the CYP mRNA level in the intestine and the liver of male rats, Neuroendocrinol Lett, 32, 8 Matuskova, 2010, Effects of probiotic Escherichia coli Nissle 1917 on expression of cytochromes P450 along the gastrointestinal tract of male rats, Neuroendocrinol Lett, 31, 46 Kawauchi, 2014, Downregulation of CYP3A and P-glycoprotein in the secondary inflammatory response of mice with dextran sulfate sodium-induced colitis and its contribution to cyclosporine A blood concentrations, J Pharmacol Sci, 124, 180, 10.1254/jphs.13141FP Kawauchi, 2014, Intestinal and hepatic expression of cytochrome P450s and MDR1A in rats with indomethacin-induced small intestinal ulcers, Int J Med Sci, 11, 1208, 10.7150/ijms.9866 Bailey, 1998, Grapefruit juice-drug interactions, Br J Clin Pharmacol, 46, 101, 10.1046/j.1365-2125.1998.00764.x Ameer, 1997, Drug interactions with grapefruit juice, Clin Pharmacokinet, 33, 103, 10.2165/00003088-199733020-00003 Fuhr, 1998, Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance, Drug Saf, 18, 251, 10.2165/00002018-199818040-00002 Kupferschmidt, 1998, Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man, Br J Clin Pharmacol, 45, 355, 10.1046/j.1365-2125.1998.t01-1-00687.x Eagling, 1999, Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein–mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components, Br J Clin Pharmacol, 48, 543, 10.1046/j.1365-2125.1999.00052.x Kanazawa, 2001, The effects of grapefruit juice on the pharmacokinetics of erythromycin, Eur J Clin Pharmacol, 56, 799, 10.1007/s002280000229 Guo, 2000, Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity, Jpn J Pharmacol, 82, 122, 10.1254/jjp.82.122 Lown, 1997, Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression, J Clin Investig, 99, 2545, 10.1172/JCI119439 Bártíková, 2014, Effect of standardized cranberry extract on the activity and expression of selected biotransformation enzymes in rat liver and intestine, Molecules, 19, 14948, 10.3390/molecules190914948 Zhu, 2012, Role of intestinal cytochrome p450 enzymes in diclofenac-induced toxicity in the small intestine, J Pharmacol Exp Ther, 343, 362, 10.1124/jpet.112.198077 Zhang, 2013, Dietary regulation of mouse intestinal P450 expression and drug metabolism, Drug Metab Dispos, 41, 529, 10.1124/dmd.112.049403 Zhu, 2014, Regulation of intestinal cytochrome P450 expression by hepatic cytochrome P450: possible involvement of fibroblast growth factor 15 and impact on systemic drug exposure, Mol Pharmacol, 85, 139, 10.1124/mol.113.088914 Sim, 2010, The Human Cytochrome P450 (CYP) Allele Nomenclature website: a peer-reviewed database of CYP variants and their associated effects, Hum Genom, 4, 278, 10.1186/1479-7364-4-4-278 Gomez, 2009, Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein, Pharmacogenomics, 10, 1067, 10.2217/pgs.09.56 Tamási, 2011, Role of xenobiotic metabolism in cancer: involvement of transcriptional and miRNA regulation of P450s, Cell Mol Life Sci, 68, 1131, 10.1007/s00018-010-0600-7 Ikemura, 2014, MicroRNAs as regulators of drug transporters, drug-metabolizing enzymes, and tight junctions: implication for intestinal barrier function, Pharmacol Ther, 143, 217, 10.1016/j.pharmthera.2014.03.002 Zanger, 2014, Genetics, epigenetics, and regulation of drug-metabolizing cytochrome p450 enzymes, Clin Pharmacol Ther, 95, 258, 10.1038/clpt.2013.220 Zhang, 2009, An intestinal epithelium-specific cytochrome P450 (P450) reductase-knockout mouse model: direct evidence for a role of intestinal P450s in first-pass clearance of oral nifedipine, Drug Metab Dispos, 37, 651, 10.1124/dmd.108.025429 Ahlawat, 2014, Mice deficient in intestinal epithelium cytochrome P450 reductase are prone to acute toxin-induced mucosal damage, Sci Rep, 4, 5551, 10.1038/srep05551 Zhu, 2015, Intestinal epithelium-specific knockout of the cytochrome P450 reductase gene exacerbates dextran sulfate sodium-induced colitis, J Pharmacol Exp Ther, 354, 10, 10.1124/jpet.115.223263 D׳Agostino, 2012, Potential biological functions of cytochrome P450 reductase-dependent enzymes in small intestine: novel link to expression of major histocompatibility complex class II genes, J Biol Chem, 287, 17777, 10.1074/jbc.M112.354274 Fang, 2010, The role of small-intestinal P450 enzymes in protection against systemic exposure of orally administered benzo[a]pyrene, J Pharmacol Exp Ther, 334, 156, 10.1124/jpet.110.167742 Zhu, 2011, Role of intestinal cytochrome P450 (P450) in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specific P450 reductase knockout mouse, Drug Metab Dispos, 39, 939, 10.1124/dmd.110.037861 Doherty, 2002, The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?, Clin Pharmacokinet, 41, 235, 10.2165/00003088-200241040-00001 Hisaka, 2014, Assessment of intestinal availability (FG) of substrate drugs of cytochrome p450s by analyzing changes in pharmacokinetic properties caused by drug-drug interactions, Drug Metab Dispos, 42, 1640, 10.1124/dmd.114.059147 Amidon, 1988, Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds, Pharm Res, 5, 651, 10.1023/A:1015927004752 Kansy, 1998, Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes, J Med Chem, 41, 1007, 10.1021/jm970530e Miyaji, 2016, Advantage of the dissolution/permeation system for estimating oral absorption of drug candidates in the drug discovery stage, Mol Pharm, 13, 1564, 10.1021/acs.molpharmaceut.6b00044 Chiba, 2009, Prediction of hepatic clearance in human from in vitro data for successful drug development, AAPS J, 11, 262, 10.1208/s12248-009-9103-6 Gertz, 2008, Grapefruit juice-drug interaction studies as a method to assess the extent of intestinal availability: utility and limitations, Curr Drug Metab, 9, 785, 10.2174/138920008786049276 Galetin, 2008, Potential role of intestinal first-pass metabolism in the prediction of drug–drug interactions, Expert Opin Drug Metab Toxicol, 4, 909, 10.1517/17425255.4.7.909 Paine, 1997, Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism, J Pharmacol Exp Ther, 283, 1552 Galetin, 2010, Contribution of intestinal cytochrome P450–mediated metabolism to drug–drug inhibition and induction interactions, Drug Metab Pharmacokinet, 25, 28, 10.2133/dmpk.25.28 Choi, 2010, Effects of myricetin, an antioxidant, on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats: possible role of cytochrome P450 3A4, cytochrome P450 2C9 and P-glycoprotein inhibition by myricetin, J Pharm Pharmacol, 62, 908, 10.1211/jpp.62.07.0012 Choi, 2010, Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin, Eur J Clin Pharmacol, 66, 285, 10.1007/s00228-009-0757-x Choi, 2011, Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin, Pharmacol Rep, 63, 1574, 10.1016/S1734-1140(11)70724-1 Cho, 2011, Effects of the antioxidant baicalein on the pharmacokinetics of nimodipine in rats: a possible role of P-glycoprotein and CYP3A4 inhibition by baicalein, Pharmacol Rep, 63, 1066, 10.1016/S1734-1140(11)70624-7 Cho, 2012, Effects of curcumin on the pharmacokinetics of tamoxifen and its active metabolite, 4-hydroxytamoxifen, in rats: possible role of CYP3A4 and P-glycoprotein inhibition by curcumin, Pharmazie, 67, 124 Chen, 2013, Hepatic and gastrointestinal first-pass effects of vitexin-4ʹʹ-O-glucoside in rats, J Pharm Pharmacol, 65, 1500, 10.1111/jphp.12121 Choi, 2013, Effects of nifedipine on the pharmacokinetics of repaglinide in rats: possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine, Pharmacol Rep, 65, 1422, 10.1016/S1734-1140(13)71502-0 Choi, 2016, Effects of pioglitazone on the pharmacokinetics of nifedipine and its main metabolite, dehydronifedipine, in rats, Eur J Drug Metab Pharmacokinet, 41, 231, 10.1007/s13318-014-0249-y Matsuda, 2012, Assessment of intestinal availability of various drugs in the oral absorption process using portal vein-cannulated rats, Drug Metab Dispos, 40, 2231, 10.1124/dmd.112.048223 van Herwaarden, 2007, Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism, J Clin Investig, 117, 3583, 10.1172/JCI33435 van Waterschoot, 2009, Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam, Drug Metab Dispos, 37, 2305, 10.1124/dmd.109.029397 van Waterschoot, 2008, Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes, Mol Pharmacol, 73, 1029, 10.1124/mol.107.043869 Granvil, 2003, Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam, Drug Metab Dispos, 31, 548, 10.1124/dmd.31.5.548 Gertz, 2010, Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data, Drug Metab Dispos, 38, 1147, 10.1124/dmd.110.032649 Gertz, 2011, Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction, Drug Metab Dispos, 39, 1633, 10.1124/dmd.111.039248 Karlsson, 2013, Utility of in vitro systems and preclinical data for the prediction of human intestinal first-pass metabolism during drug discovery and preclinical development, Drug Metab Dispos, 41, 2033, 10.1124/dmd.113.051664 Dufek, 2013, P-glycoprotein increases portal bioavailability of loperamide in mouse by reducing first-pass intestinal metabolism, Drug Metab Dispos, 41, 642, 10.1124/dmd.112.049965